awmsg logo



dolutegravir (Tivicay®)


Reference No. 843

Publication date:
19/09/2014


Appraisal information

dolutegravir (Tivicay®) 50 mg film-coated tablet


Company: ViiV Healthcare UK Ltd
BNF category: Infections
NMG meeting date: 23/07/2014
AWMSG meeting date: 03/09/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2314
Ministerial ratification: 19/09/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Dolutegravir (Tivicay®), in combination with other anti-retroviral medicinal products, is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download